Hansa Biopharma expands leadership team with dedicated roles for Corporate Communications, Investor Relations and Business Development

Company strengthens its dedicated communications team with the appointment of Rolf Gulliksen as Head of Corporate Communication and Klaus Sindahl as Head of Investor Relations.

Emanuel Björne, previously VP Investor Relations and Business Development, will assume a new position as VP Global Business Development to fully focus on the partnership opportunities for Hansa’s proprietary enzymology platform.

Lund, Sweden, April 29, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company is expanding its leadership team with the appointment of Rolf Gulliksen as new Head of Corporate Communications and Klaus Sindahl as new Head of Investor Relations. Emanuel Björne, previously VP Investor Relations and Business Development, will assume a new position as VP Global Business Development fully focused on exploiting the increasing partnership opportunities for Hansa’s proprietary enzymology platform.

Rolf Gulliksen brings extensive experience in strategic communication from senior communication and public affairs roles within the life science industry and consultancy in Sweden and internationally. Rolf Gulliksen will be based in Stockholm.

Klaus Sindahl brings more than 15 years of broad experience in finance, M&A, and investor relations, notably at Novozymes A/S, a global leader in industrial enzymes. Klaus Sindahl holds a MSc. in Finance from Copenhagen Business School and will be based in Lund.

“As Hansa Biopharma evolves and engages with an increasing range and number of external stakeholders, we are expanding our team and creating new dedicated leadership roles. I am pleased to welcome Rolf Gulliksen and Klaus Sindahl, whose respective expertise in corporate communications and investor relations will be valuable resources to Hansa, our shareholders and the public,” said Søren Tulstrup, CEO of Hansa Biopharma. “We are grateful for Emanuel Björne’s highly regarded IR contributions over the years and are fortunate that he will now dedicate his talents to global business development, an area of increasing opportunity for Hansa, with growing interest from prospective partners for our unique enzyme technology platform.”

The information was submitted for publication, through the agency of the contact person set out below at 08:30am CET on April 29, 2019.

About Hansa Biopharma

Hansa Biopharma AB (NASDAQ Stockholm: HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product, IDEFIRIX (imlifidase), is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.

For further information, please contact:

Company:
Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Swedish Media Relations:
Cord Communications Mikael Widell
+46 (0) 703-119 960

U.K. Investor and Media Relations:
FTI Consulting
Simon Conway / Natalie Garland-Collins
+44 (0) 20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks / David Rosen (media)
+1 (212) 600 1902